In the SUSTAIN-6 trial, the subcutaneous injection of semaglutide once a week reduced the relative risk of MACE by 26% compared to placebo [52]
The dedicated FLOW trial of subcutaneous semaglutide in T2D-related CKD showed a 24% reduction in the composite of major kidney disease events (HR 0.76, 95% CI 0.660.88) and significant reductions in cardiovascular outcomes [22], supporting GLP-1RA therapy as an evidence-based addition for cardiorenal protection in this population
Peptide-drug conjugates represent a growing area of development, particularly in oncology
KN receives research funding from, is a member of the advisory board for, and is a stockholder in Novo Nordisk
Whether you are using sublingual semaglutide or semaglutide troches , the compound is still a GLP-1 analog peptide that will not trigger a urine immunoassay screen
By addressing both immune dysfunction and beta cell mass loss, these convergent approaches hold promise for moving from lifelong management to a definitive cure for type 1 diabetes [134]
